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RNA interference (RNAi) effectors such as siRNA and miRNA can selectively downregulate 
any gene implicated in the pathology of a disease. Hence RNAi-based therapies present 
immense potential for the treatment of a wide range of diseases. However, pharmacokinetic 
and pharmacodynamic studies have revealed that these therapeutic agents have poor 
bioactivity due to a number of factors including insufficient plasma drug levels, short plasma 
half-lives, renal clearance and hepatic metabolism. Non-viral delivery may facilitate the 
clinical application of siRNA-based therapeutics by helping to overcome these barriers. 
Recently, the potential of gold nanoparticles (AuNPs) as multifunctional carriers for 
transporting drugs, proteins and genetic materials has been demonstrated. In this review, 
some of the key properties of AuNPs relevant to siRNA delivery such as physical properties 
and surface chemistry are described. In addition, we provide examples of AuNP-based 
formulation strategies, which have resulted in successful siRNA delivery. Finally, we 
evaluate the current limitations of siRNA nanomedicines such as delivery barriers and 
nanotoxicity and discuss potential methods to overcome these barriers achieving translational 














RNA interference (RNAi) is an endogenous mechanism of gene regulation that occurs post-
transcriptionally and that inhibits gene expression in a sequence-dependent manner. This 
occurs via either of two methods; firstly by causing degradation of corresponding mRNA or 
secondly by blocking its translation into protein [1]. RNAi is mediated by double-stranded 
RNA (dsRNA) molecules, including non-coding micro RNA (miRNA) and small interfering 
RNA (siRNA) [2]. As a high-throughput screening tool, RNAi is a powerful strategy that has 
facilitated both the discovery of disease mechanisms and the identification of potential 
therapeutic targets [3] [4]. Due to the fact that siRNA is able to effectively and specifically 
downregulate the expression of any gene, this technique has been under investigation for the 
treatment of various diseases [5] [6] [7]. However, many challenges associated with the use 
of siRNA have to be addressed before the clinical application of siRNA-based therapeutics 
can be fully realised. These challenges include insufficient plasma drug levels, short plasma 
half-life, renal clearance and hepatic metabolism [8].  
Viral particles were traditionally used for RNAi delivery as they are known to generate long-
term gene silencing by integrating small hairpin RNA (shRNA) expression cassettes into the 
cell genome and can be manipulated for specific tissue tropism [9]. However their use has 
been limited by the potential for insertional mutagenesis leading to dysregulated gene 
expression in the target cell [10]. In addition, viral vectors can be removed from the 
bloodstream by pre-existing antibodies and tend to trigger complement and coagulation factor 
activation, leading to severe immunogenicity problems [11]. Furthermore, the clinical use of 
viral delivery vectors has been impeded by difficulties with large-scale production and cost-
inefficiency. As a result, clinical trials involving viral-vector based gene therapies have 
steadily declined over the past decade (comprising only 19.7% of trials in 2012 compared to 
22.8% in 2007 and 28% in 2004), while the number of non-viral vector trials has grown over 
the same period [12]. Indeed, various non-viral delivery constructs have been investigated in 
recent years and offer great potential for facilitating the development of successful siRNA 
nanomedicines [5] [6] [7].  
Gold possesses a number of attractive properties as a bulk metal, including high electrical 
conductivity, reflectivity, malleability and resistance to corrosion and oxidation [13]. 
Recently, this metal has demonstrated various promising properties when it is finely tuned 
into the nanoscale size range (1~100 nm). For instance, because of their unique physical, 
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chemical and optical properties, gold nanoparticles (AuNPs) have been widely utilised in 
biomedical applications such as clinical chemistry, immunoassays, optical imaging, 
monitoring of cells and tissues and as biosensors [14-17]. The gold core of these 
nanoparticles (NPs) is generally inert, non-toxic and biocompatible and thus is considered a 
favourable starting material for carrier construction. Indeed, bioengineered multifunctional 
AuNPs demonstrate potential for transporting a variety of therapeutic cargos (i.e. drugs, 
proteins, genetic materials and small molecules) to their sites of action without showing 
significant adverse effects [18] [19] [20] [21].  
In this review, our focus will be directed towards AuNPs used as siRNA nanomedicines. In 
this regard, we highlight some of the key features of AuNPs for siRNA delivery, such as size 
and shape dependent physical and chemical properties. In addition, we provide examples of 
AuNP-based vectors and describe formulation strategies that have achieved successful siRNA 
delivery. Challenges associated with siRNA nanomedicines including delivery barriers and 
nanotoxicity will be evaluated and approaches to overcome these hurdles using AuNPs will 
be discussed. Finally, we outline an ‘ideal’ multifunctional AuNP for siRNA nanomedicines, 
based on a critical analysis of the approaches discussed in the review.   
 
2.   Development of gold nanoparticles for siRNA delivery 
2.1 Key properties of gold nanoparticles 
AuNPs have recently been utilised for diagnosis and drug delivery due to their favourable 
pharmaceutical properties which include relatively bio-inert surfaces, easily modified surface 
chemistry, and the high degree of control over size and shape offered during synthesis [13] 
[22]. Key properties of AuNPs for siRNA delivery, namely physical properties (i.e. optics 
and structures) and surface chemistry (i.e. functional moieties and targeting ligands 
conjugation), will now be further discussed (Fig. 1). 
Figure 1. 
2.1.1 Physical properties 
Gold has been used since the 17th century as a ruby pigment for stained glass. In 1857 
Michael Faraday demonstrated that the red colour was due to metallic gold in colloidal form, 
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a discovery that was later followed in 1908 by the explanation of such optical properties by 
Gustav Mie [13]. The unique optical properties of AuNPs are now well known to be due to 
their Surface Plasmon Resonance (SPR), a phenomenon associated with coherent oscillations 
of conduction-band electrons on nanoparticle surfaces in the three dimensions of space, 
giving rise to localised surface plasmon resonance (LSPR) upon interaction with light [23-
25]. LSPR generates light absorption, scattering phenomena and fluorescence (Fig. 1). The 
application of these major optical processes has been discussed at length by Huang et al [26]. 
In general, the SPR depends on particle morphology (i.e. size and shape), the surrounding 
environment and the aggregation state of the NP [27-31].  
Morphology: Recent advances in AuNP synthesis have improved size distribution and 
facilitated particle size control within the range of 9-200 nm during synthesis in aqueous 
media [31-36]. It was reported that when the size of AuNPs was over 15-20 nm the plasmon 
was shifted to a higher wavelength, which resulted in a change of colour of the colloidal 
solution from red to red-grey [24, 37]. In contrast, both a blue-shift and a red-shift have been 
observed by decreasing the particle size [24, 32-35, 37]. The technique of UV-visible 
spectrophotometry has been used to assess the particle size difference in relation to 
modification (i.e. PEGylation, stabilising ligands, silica encapsulation and targeting ligands) 
of AuNPs which are designed to achieve a multifunctional carrier for siRNA delivery. 
In addition, SPR is also sensitive to changes in the shape of particles [38, 39]. Geometric 
changes cause a variation in density of the electric field on the AuNP surface, leading to 
alterations in the oscillation frequency of the electrons, thereby producing different optical 
characteristics, such as absorption and scattering [28, 40-43]. For example, the plasmon 
absorption of gold nanorods is divided into two bands corresponding to the oscillation of free 
electrons along axes perpendicular and transverse to the axis of nanorods [44, 45]. Therefore 
the spectrum of nanorods in solution shows a transverse mode resonance at about 520 nm, 
which coincides with that of the plasmon band of spherical particles, while the resonance of 
the longitudinal mode is shifted to the red, strongly depending on the aspect ratio ‘AR’ 
(defined as the length divided by the width of the nanorods) [46]. Particle shape of AuNPs is 
now known to play an important role in biological stability and cellular uptake, which can 
significantly influence siRNA delivery (see reviews in section of 3.1.2).  
Moreover, gold nanoshells and nanocages are known to absorb light in the Near-Infra Red 
(NIR), making them interesting materials as contrast agents for imaging probes in the NIR 
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and as photothermal therapy for cancer treatment [47-50]. Recently, NIR has been utilised to 
assist escape of AuNP-based siRNA delivery systems from endosomes/lysosomes, one of 
critical barriers for successful siRNA delivery (see reviews in section of 3.1.2). 
Environments and aggregation state: The dielectric constant of the surrounding environment 
plays a key role in determining both the position of the plasmon maximum and its intensity. 
For instance, this occurs during transfer of AuNPs from water to a transparent oxide matrix 
[51]. Mulvaney et al. showed that a plasmon band red-shift was observed for silica-coated 
AuNPs due to an increase in thickness of the silica shell that altered the dielectric constant 
locally around the particles [52]. Moreover, Underwood showed that the colour of a colloidal 
solution of AuNPs synthesised in water (n = 1.336) and in a mixture of butyl acetate (n = 
1.38) and carbon disulphide (n = 1.62) changed from pale red to purple due to a displacement 
of the plasmon band of about 23 nm towards higher wavelength [53].  
In addition, the interparticle distance and aggregation state of NPs strongly affect the SPR 
band. Ung et al. synthesised composite of homogeneous monolayer films from silica-coating 
AuNPs with a control of the silica shell thickness and the AuNPs interparticle distance [54]. 
The distance between the particles is controlled directly by altering the thickness of the silica 
layer and it has been shown that the observed colour of AuNPs varies greatly with the 
interparticle distance. Enlargement of the plasmon and a red shift were seen due to coupling 
between the AuNPs cores, and when the distance was shorter, the resonance frequency 
became lower [54]. In addition, Maye and colleagues [55] used multidentate thioether ligands 
as molecular mediators to form spherical assemblies of controllable size (20 to 300 nm in 
diameter) with small diameter AuNPs (5 nm) stabilised by tetraalkylammonium. The UV-
visible spectrum showed a change in absorbance or wavelength of the plasmon band in 
response to the addition of various thioether/AuNPs ratios to NPs. This change provided a 
measure of particle assemblies’ size, shape and aggregation or elongation state. 
Due to these aforementioned SPR properties the techniques of UV-visible spectrophotometry 
inductively coupled plasma atomic emission spectroscopy (ICP-AES), light-scattering system 
(DLS), transmission electron microscopy (TEM), and bright-field and dark-field microscopy, 
can be used to determine the size, shape and polydispersity of AuNP-based siRNA delivery 
systems and monitor their tissue distribution, cellular internalisation and intracellular 
trafficking [56] [57], all of which play critical roles in controlling AuNP pharmacokinetics 
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(PK) and pharmacodynamics (PD) for successful systemic delivery of siRNA (see reviews in 
section 3.1).  
2.1.2 Surface chemistry 
The inherent surface chemistry of gold contributes to making AuNPs a promising platform 
for biomedical applications. There are a number of methods available for the chemical 
synthesis of AuNPs (i.e. Brust-Schiffrin method, Turkevich-Frens approach and Hussain 
method) [58]. AuNP synthesis is typically started using the commercially available agent 
HAuCl4 which acts as a gold precursor [19]. The gold precursor is reduced by the addition of 
a reducing agent which results in the nucleation of Au ions into AuNPs [14]. In addition, a 
stabilising agent is used that is either adsorbed or chemically bound to the surface of the 
AuNP [19]. A typical reducing agent often used is trisodium citrate (sometimes referred to 
simply as sodium citrate) that acts as both a reducing and stabilising agent. As trisodium 
citrate is typically charged, the equally charged AuNPs repel each other, thereby providing 
the final AuNP with electrostatic colloidal stability in aqueous media [59, 60]. A number of 
reducing and stabilising agents that are commonly used for AuNP production in both water 
and organic solvent are further discussed by Rana et al. [61]. In addition, it is interesting to 
note that the application of biological routes (i.e. the green nanotechnology) has been recently 
developed to facilitate the formation of AuNPs [62] [63] [64], which can achieve tuneable 
sizes and shapes of gold nanostructures instead of chemical synthetic routes based on 
conditions involving toxic chemicals. The synthesis of various gold nanostructures has been 
described by reducing Au salts with light and natural source extracts, such as plant extracts or 
extracts from fungi or microorganisms [65] [66] [67] [68]. 
Although AuNPs can be modified by a variety of surface stabilising agents including ligands, 
surfactants, polymers, dendrimers and biomolecules [14, 35, 69], the most popular method 
was demonstrated by Brust and colleagues [70]. This group used the high affinity of thiol (-
SH) to gold to produce AuNP-thiolates (Au-S). This was achieved using HAuCl4, thiol, 
tetraoctylammonium bromide and NaBH4 in water-toluene, and was stabilised via Au-S-
stabiliser bonds [70]. However, these NPs are dispersed in organic solvent and require further 
phase transfer or ligand exchange to pass them into water, as well as an essential purification 
step to remove impurities for use in biological application (i.e. siRNA delivery) [23, 71]. In 
addition, ligands containing phosphine and amine groups which similarly have high affinity 
to the surface of gold have been used as efficient stabilising agents [71].  
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These thiol, amine and phosphine groups have also been utilised to achieve AuNP 
functionalisation to anchor stabilising ligands to the surface of gold [72, 73] (Fig. 1). For 
example, PEG-SH has been used to increase stability, minimise non-specific interactions of 
serum proteins with AuNPs, and improve platelet biocompatibility [74-76]. In addition, other 
biomolecules including proteins, peptides, polysaccharides and nucleic acids, have been used 
to stabilise AuNPs using similar strategies with different linkers  [77] [78] [79]. For example, 
Helmut et al. conjugated AuNPs with Trypsin-NH2 via immobilisation through EDC/NHS 
bioconjugation onto the carboxylic functionalised AuNPs (AuNP-S-Spacer-COO-) achieving 
AuNPs-trypsin with an amide linkage in between [80]. In addition, Tao et al. synthesised 
M2e-conjugated AuNPs through thiol-gold interactions, which could be lyophilised and 
stably re-suspended in water [81]. When mice were immunised with M2e-AuNPs (M2e, the 
highly conserved extracellular region of the matrix 2 protein of influenza A virus) in 
combination with soluble CpG (cytosine-guanine rich oligonucleotide, as an adjuvant), 
animals were fully protected from challenge with lethal PR8-H1N1 influenza virus.  
In addition to the stabilising ligands that are grafted onto AuNP surfaces to maintain colloidal 
stability, AuNPs surface may also be modified with bioactive targeting ligands in order to 
achieve site-specific delivery of therapeutic cargos into a defined organ or, more specifically, 
a particular cell type [82]. Novel targeting moieties including small molecules (i.e. folic acid) 
[83], proteins/peptides [84] [85], nucleic acids [86] and antibodies [87], have been utilised for 
AuNPs to influence the tissue distribution, improve PK profile and minimise side effects to 
healthy cells [56]. Furthermore, these moieties are used to facilitate receptor mediated 
endocytosis of siRNA by cells of interest (see reviews in section 3.1.2). For example, Shiao 
et al. recently reported novel AuNPs that were synthesised via a thiol-Au linkage grafting a 
double stranded DNA [termed ds(AS1411) (a type of aptamer)] onto the surface of AuNPs, 
that can specifically target cancer cells that overexpress nucleolin [88]. These targeted 
AuNPs were then used as effective carriers for the delivery of anticancer drugs (doxorubicin 
(Dox)) and a photosensitizer (TMPyP4) to HeLa cells (a nucleolin positive cancerous cell 
line) [88]. Moreover, Arosio et al. demonstrated novel AuNPs capped with α-fucosyl-β-
alanyl amide that can effectively bind cellular DC-SIGN, one of the best characterised 
carbohydrate-specific receptors in dendritic cells (DCs) [89]. These AuNPs with different 
sugar densities (15%, 30% and 50% of fucosylamide) demonstrated high water solubility and 
excellent dispersion; when AuNPs bound to DC-SIGN expressing cells they induced DC-
SIGN internalisation without inducing DC maturation or elevating anti-inflammatory 
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cytokine IL-10, implying a possible application as imaging tools and antigen delivery devices 
[89]. However, it is worth noting that the targeted delivery strategy is highly dependent on 
the ratio of overexpression of the targeting receptor on the desired cells compared to other 
tissues [90] [91]. 
2.2 Formulation of gold nanoparticles - siRNA delivery strategies  
As aforementioned, AuNPs can be functionalised by grafting biocompatible polymers and 
natural or synthetic biomolecules onto the surface of gold in order to achieve a 
multifunctional carrier. In this section, selected examples of AuNP-based vectors are 
provided and their formulation strategies, including chemisorption, electrostatic interaction 
and layer-by-layer self-assembly (Fig. 1), are described in order to facilitate an siRNA 
delivery system and also to allow for site-specific administration and controlled release 
(Table I).  
Table I. [69, 92-122] 
2.2.1 Chemisorption 
Due to the high affinity of thiol (-SH) to gold to produce AuNP-thiolates (Au-S), thiol-
functionalised siRNA (siRNA-SH) has been used to attach onto AuNPs thus forming a 
complex. Patel and co-workers evaluated the structural requirements of siRNA for Dicer 
recognition and serum stability when prepared with AuNPs [101]. In this study, 26 to 28 
base-pair pre-siRNA with a variety of modifications were chemisorbed onto citrate-stabilised 
AuNPs (13 ± 1 nm) via the thiol group on the sense of pre-siRNA. The siRNA modifications 
included a 2-base overhang, a blunt A-U end, a blunt G-C end, pentose sugar modification 
with LNAs and modification of the phosphate backbone using a phosphorothioate (P=S) link. 
The results showed that by altering nucleic acids to contain certain features such as changing 
the 3’-end overhang, making a blunt A-U end or incorporating LNA and P=S, the siRNA was 
preferentially recognised by Dicer to generate functional siRNA. However, these 
modifications of siRNA also caused unwanted dramatic serum degradation of pre-siRNA. In 
contrast, pre-siRNA modified with a blunt G-C end was significantly resistant to serum 
degradation without compromising Dicer recognition. More importantly, AuNPs containing 
pre-siRNA with a blunt G-C end demonstrated increased cellular uptake and improved Green 
Fluorescent Protein (GFP) gene knockdown in comparison to other siRNA modifications. 
These results suggest that minor changes in nucleic acid structural properties can dramatically 
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influence Dicer processing, serum stability, cellular uptake and gene knockdown of siRNA-
AuNPs [101]. 
Novel spherical nucleic acid nanoparticle conjugates (SNA-NCs) were developed by Zheng 
and co-workers. These NPs possess a gold core surrounded by a dense shell of highly 
oriented, covalently immobilised thiolated siRNA [104]. SNA-NCs containing siRNA against 
EGFR achieved improved gene silencing compared to siRNA delivered with commercial 
lipid agents in cultured keratinocytes. In addition, topical delivery of 50 nM SNA-NCs (1.5 
µM EGFR siRNA) for 3 weeks to hairless mouse skin dramatically reduced EGFR 
expression, suppressed downstream ERK phosphorylation, and decreased epidermal 
thickness by ~40%, without showing clinical or histological evidence of toxicity. These 
results suggested that topical delivery of SNA-NCs may be promising for cutaneous tumours, 
skin inflammation, and dominant negative genetic skin disorders. 
Furthermore, it was reported that folate receptor-targeted hollow gold nanospheres carrying 
siRNA via thiol groups against the NF-kappaB p65 subunit could achieve downregulation of 
the targeted gene when induced by NIR light [106]. The NF-kappaB transcription factor itself 
is known to regulate the expression of genes involved in tumor formation and progression. 
The results of micro-positron emission tomography/computed tomography imaging showed 
that the targeted NPs generated higher tumor uptake than non-targeted counterparts following 
i.v. administration to mice xenografted with cervical cancer cells. When combined with NIR 
light irradiation, the targeted NPs demonstrated efficient and controllable intracellular 
trafficking of siRNA. It is worth noting that efficient silencing of NF-kappaB p65 was 
achieved only in tumours irradiated with NIR light but not in non-irradiated tumours grown 
in the same mice [106]. In addition, no significant adverse effect was found on major organs 
including the liver, spleen, kidney and lung. These data suggest that AuNP-based RNAi 
therapeutics may benefit from NIR light that can penetrate the skin and be delivered with 
high spatiotemporal control, while avoiding unwanted side effect. 
2.2.2 Electrostatic interaction 
In addition to attachment of siRNA onto gold via thiol groups, negatively charged siRNA can 
also be condensed or complexed by AuNPs with positively charged groups via electrostatic 
interaction. It is known that electrostatically stabilised citrate-AuNPs have very limited 
applications due to their fast aggregation in complex media with high ionic strengths, i.e. in 
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biological fluid [35]. Therefore, the dispersion of AuNPs must be controlled to provide a 
better platform for the advancement of these materials in catalytic and biological applications. 
Recently, it has been reported that the synthesis of well dispersed AuNPs (5 to 60 nm) was 
achieved in water and under physiological conditions (0.15 M NaCl). This was achieved by 
attaching PEG-thiol (mPEG-SH) as a stabilising ligand to the surfaces of AuNPs making 
them suitable for application in biology and catalysis [69]. The results showed the PEG-
AuNPs with diameters <30 nm were useful as catalysts in the homocoupling of arylboronic 
acids in water; whereas citrate-AuNPs (5, 15, 30 and 60 nm) had minimal catalytic efficiency 
due to their aggregation in the reaction media. siRNA was then condensed with protamine (a 
small, arginine-rich, nuclear protein that has been used for enhancing nucleic acid 
transfection) to achieve cationic ‘protamine.siRNA’ and complexed with the partially 
negatively charged PEG-AuNPs, with the final formulation demonstrating favourable cell 
viability, effective cellular uptake and successful in vitro luciferase gene knockdown [69]. 
In addition, synthesis of PEI-coated AuNPs using catechol-conjugated PEI (PEI-C) was 
developed for siRNA delivery [110]. Since the conjugated catechol groups are reductive and 
moderately hydrophobic, PEI-C formed spherical multi-cored micelles in aqueous solution 
and served as reductive templates for the growth and synthesis of spherical AuNPs with 
tunable sizes and surface charges. PEI-C was stably anchored on the surface of growing 
crystal gold seeds, resulting in robust cationic AuNPs to effectively complex siRNA. The 
siRNA-PEI-C-AuNP complexes with an average diameter of 15.3 nm and a surface zeta-
potential value of +5 mV showed significantly higher GFP suppression than counterparts that 
have larger diameters and higher surface charge values, indicating that particle size and 
surface charge had a great influence on gene silencing efficiency. Interestingly, the PEI-
capped AuNPs exhibited an extremely low cytotoxicity, most likely due to the reduced 
density of primary amine groups and the absence of free PEI in aqueous solution [110].  
Recently, Kong and co-workers developed cationic lipid-coated AuNPs (L-AuNPs) for 
efficient intracellular delivery of therapeutic siRNA [111]. In this study, hydrophobic 
dodecanethiol-capped AuNPs with an average size of 5 nm were first produced and then 
solubilised in an organic solvent with three different lipid components (3β-[N-(N′,N′-
dimethylaminoethane)-carbamoyl]-cholesterol (DC-Chol), L-α-dioleoyl 
phosphatidylethanolamine (DOPE), and cholesterol). The subsequent emulsification and 
solvent evaporation processes resulted in the swift assembly of the amphiphilic lipid building 
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blocks around the AuNPs via hydrophobic interactions, achieving a final L-AuNP with an 
outer cationic lipid shell and an inner AuNP core allowing them to be dispersible in water. L-
AuNPs were shown to effectively condense siRNA and demonstrated efficient cellular uptake 
and gene knockdown (i.e. GFP, VEGF, Ubiquitin B, and Hepatitis B Virus Surface Antigen) 
in a variety of cell lines including MDA-MB-435 (human melanoma cells), A549 (human 
lung carcinoma cells), PC3 (human prostate carcinoma cells), HepG2 (human Hepatocellular 
carcinoma cells), and HepG2.2.15 (Hepatitis B virus (HBV)-producing hepatocellular 
carcinoma cells). In addition, L-AuNPs did not induce any significant cytotoxicity. These 
results suggest that L-AuNPs are an efficient and safe siRNA delivery construct which could 
potentially be used for the treatment of a variety of diseases. 
2.2.3 Layer-by-layer self-assembly 
Layer-by-layer (LbL) assembly is a prominent method of AuNP formulation for siRNA 
delivery in which multi-layered films with tailored properties can be fabricated on substrates 
[123]. This method has been used to prepare AuNPs with multi-layered shells through 
particle templating [124]. For instance, Elbakry et al. reported an LbL strategy whereby 
citrate-AuNPs were modified with mercaptoundecanoic acid (MUA), resulting in a more 
stable negatively charged MUA-AuNPs [119]. The MUA-AuNPs were electrostatically 
interacted with PEI (PEI-MUA-AuNPs) which formed a cationic outer layer that efficiently 
complexed siRNA (siRNA-PEI-MUA-AuNPs) resulting in AuNPs with an anionic outer 
layer. Finally, siRNA-PEI-MUA-AuNPs were coated by PEI to form PEI-siRNA-PEI-MUA-
AuNPs in which siRNA is sandwiched between two layers of PEI polymer and a cationic 
outer surface. This final formulation demonstrated efficient endosomal escape and effective 
Enhanced Green Fluorescence Protein (EGFP) gene silencing in CHO-K1 cells stably 
expressing EGFP. More importantly, this LbL approach to preparing AuNPs is an excellent 
tool to study how the size and the surface properties of delivery systems influence siRNA in 
terms of their cellular uptake, endosomal escape and release into cytoplasm [119]. 
Another LbL approach was demonstrated by Han and co-workers using chitosan (CS), 
poly(allylamine hydrochloride)-citraconic anhydride (PAH-Cit) and PEI [158]. In this work, 
AuNPs were reduced and stabilised by CS, resulting in a cationic AuNP-CS. This was then 
used to condense PAH-Cit at pH 7.4 (PHA-Cit is a pH-responsive charge-reversible polymer, 
being anionic at physiological pH but cationic at acidic pH). This formed PAH-Cit-CS-
AuNPs with a negatively charged outer layer. Subsequently, PEI was deposited onto PAH-
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Cit-CS-AuNPs achieving PEI-PAH-Cit-CS-AuNPs which could bind siRNA through 
electrostatic interaction between the cationic PEI and anionic siRNA. A subsequent in vitro 
release study demonstrated efficient siRNA release from siRNA-PEI-PAH-Cit-CS-AuNPs at 
pH 5.5, potentially facilitated by the pH-induced charge-reversing feature of PAH-Cit. 
Moreover, this formulation, when prepared with siRNA against Multidrug Resistance Protein 
1 (MDR1, the gene encoding the drug exporter P-gp), exhibited effective gene knockdown in 
drug-resistant MCF-7 cells, thereby promoting the uptake of doxorubicin [118]. 
Although PEI has been widely used for siRNA delivery to improve cell internalisation and 
facilitate endosomal escape, it causes unfavourable cytotoxicity, particularly when high 
molecular weight varieties are used and may not be biocompatible for clinical applications 
[125]. As an alternative, poly(allylamine hydrochloride) (PAH) has been used for different 
types of siRNA delivery constructs to overcome these barriers [35, 124]. Recently, a LbL 
strategy was reported by Zhao et al [115]. In this method bovine serum albumin (BSA) was 
first reduced by NaBH4 which resulted in denatured BSA (dBSA). This dBSA carried 35 
thiol groups used for capping AuNPs [115]. Due to the presence of numerous carboxyl 
groups on dBSA, dBSA-AuNPs were electrostatically coated with PAH to form a cationic 
layer (PAH-dBSA-AuNPs) which could efficiently bind siRNA (siRNA-PAH-dBSA-AuNPs). 
Subsequently, the siRNA layer was electrostatically coated with extra PAH to form the 
outermost cationic layer (PAH-siRNA-PAH-dBSA-AuNPs) which facilitated cellular uptake 
and intracellular trafficking. As a result, PAH-AuNPs containing anti-EGFR siRNA showed 
improved downregulation of EGFR in human breast cancer MCF-7 cells, in comparison with 
the commercially available vector Lipofectamine 2000®. Although PAH-AuNPs 
demonstrated similar siRNA release and gene silencing efficacy compared to PEI-AuNPs, 
PAH-AuNPs demonstrated significantly higher cell viability, making it a more suitable 
alternative for efficient in vitro and in vivo gene delivery.  
 
3. Challenges for gold nanoparticles in translational development of siRNA 
nanomedicines 
RNAi is maintained by small non-coding RNAs that mainly include siRNA and micro RNA 
(miRNA) (numerous review articles regarding RNAi have recently been published [126-
129]). It is possible to activate the siRNA-based RNAi pathway in either of two ways [130]: 
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(A) plasmid-, bacterial- or viral-based vectors delivering therapeutic DNA to the nucleus 
result in the transcription of shRNA. This is exported to the cytoplasm where it is recognised 
by Dicer. Dicer is an enzyme that cleaves dsRNA and pre-micro RNA (pre-miRNA) into 
siRNA and miRNA, respectively. Thus shRNA is processed into siRNA [~19-23 base pairs 
(bps) with 2-nucleotide (nt) 3’ overhangs] for subsequent RISC loading. (B) Synthetic siRNA 
is introduced into the cytoplasm, bypassing the nucleus transcription of DNA step, to directly 
allow RISC loading. When siRNA is loaded into the RNA-induced silencing complex (RISC, 
a multiprotein complex) the sense strand is removed and the antisense strand retained to 
produce antisense-RISC. This complex can achieve sequence-specific cleavage of perfect (or 
nearly perfect) matching messenger RNA (mRNA) targets. In contrast, miRNA primarily 
binds to the 3’ un-translated regions (UTRs) of imperfectly complementary mRNA and 
induces translational suppression or transcript deprivation via RISC [127]. 
Over the past decade, RNAi has been widely used for both in vitro and in vivo high-
throughput screening, facilitating the discovery of disease mechanisms and the identification 
of potential therapeutic targets  [3] [4]. Recent advances in our knowledge of molecular 
genetic data, facilitated by sequencing the genome of malignant cells, has resulted in 
significant changes in our understanding of the molecular pathogenesis of many diseases (i.e. 
many types of cancer, infection diseases and genetic disorders) [131-133] and has facilitated 
the identification of a number of molecular targets against which siRNA and miRNA have 
been developed [134-137].  
Although a number of AuNP-based formulation strategies for siRNA delivery have been 
reviewed in Table 1, there are still many challenges for translational development of AuNPs 
to achieve siRNA nanomedicines. New AuNP-based delivery vectors which are safe, 
efficient and effective must be developed in order to overcome the various barriers associated 
with siRNA use, administration barriers (i.e. short plasma half-lives, non-specific 
biodistribution, renal clearance and hepatic metabolism) and nanotoxicity. 
3.1 Delivery barriers 
3.1.1 Local administration 
When designing a carrier construct for siRNA delivery one of the first decisions is whether to 
develop the formulation for local or systemic administration. Local administration involves 
delivery of siRNA therapeutics directly into target tissues. This delivery method is known to 
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offer several advantages over systemic delivery, including lower doses, ease of access, 
facilitation of site-specific delivery and fewer adverse effects [138]. Indeed, successful local 
delivery of siRNA into several tissues, such as the foot, skin, eye, mucus membranes and 
tumours, has been demonstrated as shown in [138]. Recently, multifunctional AuNPs for 
local administration have been designed based on changes in the local environment [56]. For 
instance, Cole et al. developed bisphosphonate-functionalised AuNPs (BP-AuNPs) that 
facilitate improved sensitivity and specificity for the detection of microcalcifications which 
are deposits of hydroxyapatite (HA) mineral within breast tissue and the most common 
abnormality detected by mammography for breast cancer compared to other surrounding 
tissues [139]. After intra-mammary administration in a mouse breast tumour model, BP-
AuNPs provided enhanced contrast for the detection of microcalcifications that were 
otherwise below the computed tomography (CT) detection limit.   
Physical approaches including microneedle, electroporation, ultrasound and magnetic 
stimulation may improve local administration of therapeutic cargos [140-143]. For instance, 
it has been reported that the transfection efficiency of AuNPs carrying a DNA plasmid was 
improved ~1.5−2 fold when combined with electroporation without inducing any toxicity 
[109]. In addition, Wang et al. improved the delivery of gold nanorods by combining three 
mechanisms: gold nanorods encapsulated in protein-shell microbubbles (AuMBs), molecular 
targeting (anti-VEGF receptor 2), and sonoporation employing acoustic cavitation of 
microbubbles (MBs) [142]. Following intravenous injections in mouse xenograft models, 
targeting AuMBs could bind to the angiogenesis marker and stay at the tumour site over a 
longer period of time compared to nontargeting counterpart; when tumour areas were treated 
with ultrasound, MBs were destroyed to release gold nanorods that could subsequently enter 
into cells due to acoustic cavitation induced during MB destruction by sonoporation (i.e. 
increase in transient cellular permeability) [142]. These studies imply that the combination of 
a physical and chemical delivery concept may facilitate local administration of AuNP-based 
siRNA delivery systems.  
3.1.2 Systemic circulation 
Although local siRNA delivery has presented therapeutic potential for the treatment of 
disease in several instances, many diseases (e.g. metastatic cancers) can only be treated via 
systemic administration of therapeutic agents into the bloodstream [2, 138]. Here, we discuss 
AuNP-based approaches to overcome problems associated with systemic siRNA delivery 
16 
 
including serum degradation, instability in the circulation, targeting to specific cells of 
interest, activation in response to the local environment and endosomal escape (Fig. 2).   
Figure 2. 
Serum degradation: Unprotected siRNA is rapidly degraded in the plasma/serum due to the 
susceptibility of nucleic acids to degradation by serum nucleases. As described in section 2.2, 
the formulation of siRNA with AuNPs can be achieved using different methods and may 
offer the benefit of providing steric protection of siRNA from serum nucleases [130].   
However, it is important to note that tight binding or condensation of siRNA may also 
potentially impair gene silencing efficacy, mostly like due to inefficient or incomplete release 
of siRNA from NPs that are too tightly associated [144]. Therefore, efforts must be made to 
balance the binding strength between the two, so that AuNPs will allow both protection of 
siRNA from serum degradation in the initial stages after administration, while also allowing 
the release of siRNA into the cytoplasm where it can exert its therapeutic effect. 
Instability in the circulation: Considering the high surface to volume ratio of AuNPs, 
systemic circulation of AuNPs in bloodstream may induce non-specific binding of plasma 
proteins causing large particles and therefore, may be taken up by the reticuloendothelial 
system (RES) [also known as mononuclear phagocyte system (MPS)] in a process known as 
opsonisation [2]. This phenomenon leads to recognition and removal of NPs from the blood 
by circulating phagocytes and tissue macrophages (mainly the hepatic Kupffer cells and the 
marginal zone and red-pulp macrophages in the spleen) [145, 146], which can eventually 
result in large particles trapped in the liver and lung and, to a lesser extent, in the kidneys and 
spleen [147].  
It is interesting to note that particle shape of AuNPs may also play an important role in 
protein adsorption, therefore controlling their PK profiles. AuNPs are easily tailored into 
various structures, such as gold nanospheres, gold nanorods, gold nanostars, gold non-
pyramids and gold nanocages. Among them, Au nanospheres and Au nanorods have been 
substantially studied for biomedical application, especially in imaging and drug delivery 
[148]. Recently, direct interaction of bovine serum albumin (BSA) with gold nanospheres and 
nanorods was investigated to confirm the interaction of protein with AuNPs [149]. In this 
study, the binding constants for BSA to 10 nm anionic citrate-capped gold nanospheres and 
cationic CTAB-conjugated gold nanorods (aspect ratio of 2.3) were 2.34 x 1011 M-1 and 5 x 
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104 M-1, respectively. The same approach was also used to calculate the binding constants of 
BSA to 14 nm citrate-capped gold nanospheres (1.7 x 108 M-1) and CTAB-capped gold 
nanorods of aspect ratio 3 (1.3 x 107 M-1) and 8 (2.7 x 107 M-1) [150], suggesting that the 
interaction of proteins onto various AuNPs with a variety of shapes, sizes and surface 
functionalities need to be substantially studied.  Due to the physical characteristics of AuNPs 
(reviewed in section 2.1.1), spectroscopic techniques that follow the shifts in the LSPR bands 
have been utilised to determine the interaction of different proteins with AuNPs [151]. Other 
analysis methods including isothermal titration calorimetry (ITC), quartz crystal 
microbalance (QCM), circular dichroism (CD), dynamic light scattering (DLS), gel 
electrophoresis and mass spectrometry, have also been used to study the protein-NP 
interactions [152]. 
One of the most widely characterised methods to avoid MPS uptake is the addition of neutral 
stabilising components to the surface of NPs [e.g. PEG (Polyethylene glycol), block 
copolymers and hyaluronic acids] to form so called ‘stealth’ particles [153]. Such 
modifications stabilise complexes against salt-, protein- and complement-induced 
inactivation by steric effects as well as by shielding surface charge. Indeed, PEGylation of 
non-viral vectors has been used to improve stability and prolong blood circulation time of 
siRNA delivery systems [154-156].  
Although the hydrophilic PEG chain is considered to be biocompatible, non-toxic, non-
immunogenic and non-antigenic and has been approved for use by 
the Food and Drug Administration (FDA), it is important to note that PEG has also presented 
unexpected toxicity and immunostimulation in vivo [157, 158]. For example, it has been 
recently reported that PEGylated AuNPs caused an unexpected effect on the primary function 
of erythrocytes [159]. In this study, the deformability and oxygen-delivering ability of 
erythrocytes were decreased due to the interaction between PEGylated AuNPs and 
erythrocyte membranes, implying how a careful design is required for PEG-functionalised 
AuNPs for biomedical applications.   
In addition, it is of interest to note that certain surface-adsorbed proteins (e.g. opsonic 
proteins, antibodies in the blood), rather than increasing clearance from the circulation, might 
in fact prolong nanoparticle half-life by virtue of the spatial arrangement of these non-
specific proteins (conformation, spacing and surface density) (these have been reviewed in 
[57] [160]).  
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Targeting and Environmental activation: The blood vessel walls of solid tumours are 
typically ‘leakier’ that those found in healthy tissues. This process, termed angiogenesis, is a 
critical step in the transformation of tumours from a benign to a malignant state [161]. These 
leaky vasculature and endothelial junctions provide what is known as an enhanced 
permeation and retention (EPR) effect which facilitates the entry of small particles (normally 
with diameter less than 500 nm) into sites of solid tumours (Fig. 2). Due to unique 
physicochemical features as described in section 2.1 AuNP-based siRNA delivery systems 
may present favourable size, shape and polydispersity, compliant with the requirements for 
tissue distribution through EPR effect [56].    
In addition, it has been reported by Chithrani and co-workers that cellular uptake of AuNPs is 
size- and shape-dependent [162]. In this study, the uptake half-life was 2.10, 1.90 and 2.24 h 
at a rate of 622, 1294 and 417 particles per hour for the 14, 50 and 74 nm spherical AuNPs. 
In addition, data showed that cells took up 375 % and 500 % more 14 and 74 nm gold 
nanospheres than 74 x 14 nm gold nanorods, indicating that shape is also one reason for the 
difference in uptake [162]. Although cellular uptake of these AuNPs mainly results from non-
specific binding of serum proteins, the size and shape of AuNPs appear to matter in the 
uptake, highlighting the importance of proper design of AuNPs for internalisation of siRNA.  
In order to achieve cell-specific delivery of siRNA one strategy is the conjugation of 
targeting ligands to the distal site of PEG chain to direct AuNPs to specific cell-surface 
receptors overexpressed on malignant tissues, whereupon they enter cells via receptor-
mediated endocytosis [130]. For instance, Suresh et al. synthesised and characterised a group 
of Au nanocages that were capped with bombesin (BBN) peptide toward gastrin releasing 
peptide receptors (GRPR, aberrantly expressed in numerous cancers) [163]. In this study, 
competitive cell binding and TEM results demonstrated that internalisation of Au nanocage-
BBN in prostate cancer cells results from clathrin mediated pathways, suggesting that peptide 
ligands conjugated to the surface of AuNCs maintain their target specificity.  
The specialised tumour microenvironment (TME) is adapted specifically to support the 
growth, invasion and metastasis of cancer cells [161]. For instance, physiological pH of blood 
vessels near the extracellular area of solid tumours is reduced to a slightly acidic condition 
(from pH 7.4 to ~pH 6.5-7.2) [164]. The low oxygen and acidic environment of such tumours 
are capable of triggering cancer cells with sustained tumourigenesis and can also impair anti-
cancer drug therapies which cannot function in this acidic environment [165]. Moreover, 
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extensive tumour tissue remodelling is attributed to the overexpression of many extracellular 
matrix (ECM) components (i.e. matrix metalloproteinases, MMPs) and their secretion into 
ECM [161]. Recently, a novel angiopep-2 conjugated AuNP delivery system was developed 
to respond TME and release doxorubicin (DOX) to glioma [166]. This system, namely An-
PEG-DOX-AuNPs, was associated with DOX through hydrazone (an acid-responsive linker) 
and was functionalised with angiopep-2 [a specific ligand of low density lipoprotein receptor-
related protein-1 (LRP1); it may facilitate this system to penetrate the blood brain barrier and 
target to glioma cells]. At TME pH values (i.e. 5.0 and 6.0), release of DOX was more 
efficient than that at pH 6.8 and 7.4; in a glioma mouse model, intravenous administration of 
An-PEG-DOX-AuNPs facilitated the distribution into tumour areas at a higher intensity and 
achieved longer median survival time in comparison with nontargeting PEG-DOX-AuNPs 
and free DOX, without causing significant toxicity [166]. 
Furthermore, many central nervous system (CNS) disorders (e.g. Alzheimer’s disease, 
Huntington’s disease, Parkinson’s disease and brain tumours) are extremely difficult to treat, 
largely due to the significant obstacle presented by the blood-brain barrier (BBB) (Fig. 2). 
The BBB (substantially reviewed in references [167, 168]) is a highly regulated and efficient 
barrier that limits the access of large molecules to the CNS. Recently, multifunctional NPs 
have been developed to facilitate delivery of therapeutic agents across the BBB. This has 
been achieved by modification of the delivery material with the attachment of targeting 
ligands for receptors found in neurons and the capillary endothelial cells of the BBB, such as 
the transferrin receptor, lactoferrin receptor, insulin receptor and acetylcholine receptor [85, 
168-170]. For instance, a peptide sequence THRPPMWSPVWP was conjugated onto the 
AuNPs, and this peptide sequence could interact with the transferrin receptor present in the 
micro-vascular endothelial cells of the BBB, thus causing an increase in the permeability of 
the conjugate in brain, as demonstrated by experiments in vitro and in vivo [85]. In addition, 
external stimulation factors such as light, temperature, radiofrequency, magnetic field and 
ultrasound, may also facilitate delivery of NPs across to the BBB [171], which may provide 
additive or synergistic therapeutic efficacy in combination with AuNP-based delivery 
systems.    
The potential targeting ligands that can recognise cell- or tissue-specific antigens/receptors in 
a variety of disorders, have been substantially described in [127] [85, 168-170] [172] [173], 
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which may provide great opportunities for achieving ‘smart’ bioactive AuNPs for siRNA 
delivery.   
Intracellular trafficking: NPs bind to the cell surface through electrostatic interaction and are 
generally internalised by adsorptive pinocytosis, a process whereby extracellular fluid 
together with its contents are taken into the cell to form intracellular vesicles. Alternatively, 
NPs designed with targeting ligands bind to a specific cell-surface receptor and enter the cell 
by receptor-mediated endocytosis [130]. Following cellular uptake by either pathway, NPs 
are generally entrapped inside endosomal/lysosomal vesicles that experience a drop in pH 
during vesicle progression (from pH ~5-6 in endosomes to ~4.5 in later stage lysosomes) 
which can lead to drug and nucleic acid inactivation due to the acidic conditions and the 
presence of harmful hydrolytic enzymes in such vesicles. For siRNA to reach the cytoplasm 
and exert its effect, efficient escape from these hostile environments is critical.  
AuNPs can be specifically designed to facilitate and improve endosomal/lysosomal escape in 
several ways; (A) functionalisation of AuNPs is generated with functional groups that can 
assist the release of siRNA from the endosomal/lysosomal vesicles. For example, a novel 
AuNP (GNR-DSPEI-PEG-GRD) was prepared by conjugating gold nanorods with multiple 
disulphide cross-linked short polyethyleneimine (PEI, the structure of which can be linear, 
whereby it possesses secondary amines only, or branched, which contains primary, secondary 
and tertiary amines), PEG and a terminal RGD peptide for specific targeting of integrin αvβ3-
overexpressed cancer cells [174]. The GNR-DSPEI-PEG-RGD was able to enter into cells 
via the receptor-mediated pathway and subsequently escape from endosomal/lysosomal 
compartments due to PEI-induced ‘proton sponge effect’ (a phenomena that can enhance 
endosomal Cl- accumulation and give rise to osmotic swelling and endosomal rupture) [174]. 
Other functional moieties including membrane-disruptive materials, fusogenic peptides, 
glutathione (GSH)- and pH-sensitive linkers that can facilitate release of NPs from 
endosomal membranes, have been studied in [175-177] [178], which may be conjugated to 
AuNPs, achieving bio-responsive delivery of siRNA. (B) when following excitation the 
plasmons on AuNP surfaces can decay by either radiative damping or energetic relaxation, 
which may create nonequilibrium ‘hot’ electron-hole pairs [179]. For instance, the 
aforementioned GNR-DSPEI-PEG-RGD has an aspect ratio of gold nanorods compliant with 
NIR regions; when triggered by NIR laser release of GNR-DSPEI-PEG-RGD from 
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endosomal/lysosomal vesicles was much higher than that GNR-DSPEI-PEG-RGD without 
NIR treatment [174].  
It is worth noting that intracellular trafficking studies are mainly dependent on qualitative 
comparison of immunofluorescence images and colocalisation of fluorescently labelled 
siRNA or NPs with different organelles. Alternatively, AuNPs are easily visualised by TEM, 
and bright-field and dark-field microscopy without functionalisation of fluorochrome, which 
enable quantitative characterisation of the intracellular trafficking steps and allow a more 
thorough understanding of this process [162] [174] [180].     
3.2 Nanotoxicity 
NPs are now known to induce multiple biological and genomic effects when in contact with 
living systems [181]. With the growing use of nanomaterials aiming to achieve clinically 
relevant siRNA delivery, considerable attention has been focused on understanding the 
potential side effects and toxicity of these NPs [182].  
Although bulk gold is considered bio-inert, gold exhibits different properties at nanoscale 
size during syntheses and applications. The aforementioned physicochemical characteristics 
of AuNPs (i.e. particle size, surface charge, morphology, surface coating and particulate 
aggregation) are key properties that must be tuned to facilitate efficient delivery to target 
tissues and cells, which may cause possible AuNP toxicity from their interaction with specific 
cell receptors, cell membranes or intracellular organelles. Although interaction mechanisms 
between AuNPs and biological systems are not yet fully delineated, toxicity of AuNPs may 
be investigated for any of the following concerns: (A) synthesis of gold nanostructures [65] 
[66] [67] [68]; (B) particle size, morphology and surface charge of gold nanomaterials  [183]  
[184]; (C) surface conjugates and ligands onto AuNPs  [185] [186]; (D) administration routes 
and doses of AuNPs [187] [188]; (E) other effects from interfering with the specific cell types 
(i.e. immune cells) and biological organelles (i.e. cell membrane, lysosomes, mitochondria, 
Golgi apparatus and nucleus) [189] [190] [191]. Numerous toxicological studies have been 
conducted to investigate how these factors influence AuNP toxicity, with the aim of ensuring 
any undesirable effects are avoided (see reviews in [192] [193] [194] [195] [196]).  
To date it is difficult to substantially evaluate nanotoxicity due to the lack of standardised 
approaches, inadequate models and the limitations of classical toxicological endpoints [197]. 
Nevertheless, the methods of assessing toxicity associated with bioavailability, PK, 
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persistency in the body, by-products of metabolism, cell internalisation, intercellular 
trafficking and cell interaction, are critical for both researchers and regulatory authorities 
alike. In addition, appropriate toxicity models must be carefully selected; for example, the use 
of in vitro models alone are not sufficient to measure and predict these toxicological effects, 
and further research using in vivo models for the assessment of AuNP toxicity is urgently 
required.  
 
4 Conclusions and future perspectives 
siRNA has attracted great attention in recent years owing to its capacity for highly sequence-
specific gene downregulation and almost unlimited therapeutic target choice, especially those 
considered as ‘undruggable’. To overcome the major delivery obstacles associated with 
siRNA, a variety of delivery approaches have been reported using non-viral vectors. 
Although several siRNA-based therapeutics have already entered clinical trials and are in the 
developmental pipeline, most of them are not administered intravenously but rather into the 
target tissues directly. In 2005, Kostarelos and Miller [198] reported a rational strategy to 
formulation design by classification of the formulation components in an ‘ABCD’ system 
(Fig. 2), in which ‘A’ represents the nucleic acid cargos (i.e. siRNA), ‘B’ is a 
complexation/encapsulation component, ‘C’ refers to a biological stabilising group (i.e. PEG) 
and ‘D’ represents a bioactive targeting ligand to achieve selectivity. The development of 
safe and effective ‘ABCD’ delivery systems presents great promise for siRNA administration 
for the treatment of diseases for which local delivery is not an option and that require 
systemic administration  [e.g. metastatic cancers, leukaemia and immunodeficiency syndrome 
(AIDS)].  
Successful AuNPs for diagnosis and drug delivery have been reported. Such AuNPs have 
been possible due to the unique optical properties and surface chemistry of gold (Fig. 1). As 
discussed in this review, bioengineered multifunctional AuNPs with different size, shape, 
chemistry and synthesis strategies have been designed and offer great promise in facilitating 
siRNA delivery in vitro and in vivo (Table I). However, siRNA delivery using AuNPs is still 
very much in its infancy and further investigation achieving the ‘ABCD’ nanoparticle is 
required before its widespread application can be fully realised. With advancements in the 
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design of multifunctional delivery technologies, AuNPs will consequently lead siRNA-based 
nanomedicines and the translation of gene therapy successfully from bench to bedside.  
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Table I. A summary of studies on the in vitro and in vivo delivery of antisense-
oligonucleotide (AS-ODN), miRNA and siRNA using AuNP-based strategies, including: 
formulations, effectors, targeted receptors, targeted genes, in vitro models, in vivo models 
(the route of administration) and comments. (N/A = not applicable) 
Figure 1. Development of gold nanoparticles for siRNA delivery; (1) Surface Plasmon 
Resonance (SPR) is an important feature of gold nanoparticles that results from the collective 
oscillation of delocalised electrons in response to an external electric field from light 
radiation. When AuNPs are exposed to light, many processes may occur, including re-
emission of fluorescence, Mie scattering, surface-enhanced Raman scattering and the 
photothermal effect. Since the SPR is sensitive to particle size, shape, environment and 
aggregation state, it can be used to assess the size, shape and polydispersity of AuNP-based 
siRNA delivery systems and monitor their tissue distribution, cellular internalisation and 
intracellular trafficking. (2) Commonly studied AuNPs can be categorised depending on their 
morphology, such as gold nanospheres, gold nanorods, gold nanoshells and gold nanocages. 
(3) Gold nanoparticles can be conjugated with various functional moieties, including 
therapeutic cargos (e.g. drugs, proteins, peptides or nucleic acids), charged materials, 
biological stabilising groups (e.g. PEG), ‘smart’ bio-responsive linkers, and bioactive 
targeting ligands. (4) siRNA delivery strategies using gold nanoparticles include (A) 
chemisorption (thiolated siRNA is conjugated onto the surface of AuNPs via stable Au 
linker-S bonds), (B) electrostatic interaction (AuNPs are modified with cationic moieties, 
which in turn complex siRNA via electrostatic interaction) and (C) layer-by-layer (LbL) self-
24 
 
assembly (siRNA is formulated with AuNPs which have multi-layered films with tailored 
properties). 
Figure 2. Systemic delivery of siRNA using multifunctional AuNP-based vectors: from 
administration to site of action. (1) Typical composition of multifunctional AuNPs consisting 
of (A) siRNA which can be associated with (B) AuNPs. This AB layer, can be modified by 
(C) biological stability-enhancing groups (e.g. PEG) and (D) distal targeting ligands (i.e. 
monoclonal antibodies). (2) Barriers to systemic delivery of siRNA (A) degradation by blood 
nucleases, (B) rapid renal filtration, (C) binding of unmodified AuNPs to serum proteins and 
(D) particle aggregation and opsonisation. Such barriers are overcome by utilising shielding 
materials (e.g. PEG) with/without a targeting ligand to facilitate prolonged systemic 
circulation. (3) Enhanced Permeation and Retention Effect (EPR) uptake into tumours. 
Following systemic circulation, siRNA formulations with optimum size (normally < 500 nm) 
are able to penetrate through the leaky endothelium of the tumour via the EPR effect. (4) 
siRNA uptake into the brain. siRNA formulations may cross the Blood Brain Barrier (BBB) 
via (A) receptor-mediated transport via transferrin, lactoferrin and insulin receptors, i.e. a 
molecular Trojan horse approach to induce receptor-mediated transcytosis, (B) osmotic 
disruption of tight junctions or (C) via cell-penetrating peptides and magnetic force. (5) 
‘Smart’ targeting for RNAi. (A) AuNPs can utilise either cell-specific receptors or 
extracellular environments (i.e. pH and enzymes) to enhance cellular uptake. The siRNA 
formulations are normally localised inside endosomal/lysosomal vesicles. (B) External 
stimuli such as light, temperature, electroporation, ultrasound and magnetic stimulation, may 
facilitate local administration of AuNP-based siRNA delivery systems and induce direct 
localisation of siRNA formulations inside cytoplasm. (C) Several materials such as cell 
penetrating peptides are capable of delivering siRNA into cells without entrapment inside 
endosomes. However, in most cases, AuNPs must facilitate efficient endosomal escape of 
siRNA to prevent its subsequent degradation in the late endosome/lysosome. (D) Following 
dissociation from AuNPs, siRNA in the cytoplasm is loaded into RISC which can initiate the 
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Table II. A summary of studies on the in vitro and in vivo delivery of antisense-oligonucleotide (AS-ODN), miRNA and siRNA using AuNP-based strategies, 
including: formulations, effectors, targeted receptors, targeted genes, in vitro models, in vivo models (the route of administration) and comments. (N/A = 
not applicable)  
 










AS-ODNs modified with either monothiol or 
tetrathiol were chemisorbed onto citrate-stabilised 
AuNPs 
AS-ODN N/A EGFP C166 EGFP, 
mouse 
endothelial cells 
N/A When compared with Lipofectamine® 
2000 and Cytofectin, AS-ODN-AuNPs 
demonstrated higher EGFP silencing and 
less cytotoxicity.  
 
[92] 
PEGylated AuNPs were produced via 
functionalisation of citrate-AuNPs using PEG chains 
and thiolated siRNAs were then conjugated onto 
PEG-AuNPs via thiol-gold recognition.  
AS-ODN N/A EGFP HCT-
116, colorectal 
cancer cells 
N/A siRNA-PEG-AuNPs were able to 
achieve successful gene silencing 
without showing toxicity proving more 
successful than Lipofectamine® which 
did not achieve any knockdown 
 
[93] 
Citrate-AuNPs were functionalised with cargo DNA 
conjugates that were hybridised by AS-ODN, forming 
AS-ODN-AuNPs.  











N/A The resulting constructs demonstrated 
effective targeted miRNA regulation in 
all cell lines  
 
[94] 
Citrate-capped AuNPs were first treated with diethyl 
pyrocarbonate followed by autoclaving treatment. 
The thiolated miRNA duplexes were added to the 
post-treatment AuNPs, followed by addition of 
oligoethylene glycol (OEG) thiol. 




Cell transfection and functional 
luciferase assays confirmed the delivery 
of miRNA into cells. 
 
[95] 
AuNPs were anchored by either of two miRNAs 
(miR-205 and miR-20a) thiolated at the 3’ end of the 
sense strand, forming miR-205- and miR-20a-AuNPs. 







These constructs downregulated gene 
expression up to three fold more 
effectively than analogous molecular 




Au Nanobeacons were conjugated with PEG 
stabilising groups which were then further modified 














Both NP formulations (siRNA/miRNA) 
achieved successful EGFP fluorescence 
downregulation with similar expression 
levels achieved by both 
 
[97] 
Phosphine-capped AuNPs were immobilised with 
either single-stranded antisense siRNA or single-
stranded sense siRNA. These NPs were subsequently 
crosslinked and annealed due to their 
complementarity and condensed with linear PEI  







N/A The siRNA-AuNP-PEI NP resulted in 
greater gene silencing efficacy than 
naked siRNA-PEI alone for both GFP in 
MDA-MB-435 cells and VEGF in PC3 
cells. The NPs could also be visualised 
by micro-CT imaging. 
 
[98] 
Sense strands of siRNA with an ethylene glycol 
spacer and alkylthiol were first hybridised with 
antisense strands of siRNA to achieve duplex siRNA. 
The resultant siRNA was then chemisorbed onto the 
surface of AuNPs via thiol-gold bond, which was 
followed by the passivation with a biological 














The final formulation demonstrated 
improved stability under cell culture 
conditions and enhanced efficacy of the 
bound siRNA, while retaining the ability 
to effectively knockdown the firefly 
luciferase gene. 
[99]  
The Au-S surface was modified with HS-PEG1000-
NH2 to generate NH2-PEG-AuNPs. These were 
further conjugated with a disulphide linker allowing 
the chemisorption of thiolated siRNA to produce 
siRNA-PEG-AuNPs. NPs were then coated with a 
variety of end-modified poly(β-amino esters) 













N/A For optimised formulations siRNA-
PEG-AuNP-PBAEs showed 
significantly higher firefly luciferase 
gene knockdown than the commercially 




Sense strands of siRNA with an ethylene glycol 
spacer and alkylthiol were first hybridised with 
antisense strands of siRNA to achieve duplex siRNA. 













AuNPs functionalised with a blunt G-C 
ended siRNA had increased stability, 
significantly higher cellular uptake and 
improved gene knockdown relative to 
 
[101] 
surface of AuNPs via thiol-gold bond, which was 
followed by the passivation with a biological 
stabilising group (oligoethylene glycol-thiol). 
other siRNA modifications 
An i-motif-based DNA AuNP was synthesized that 
utilised pH-responsive dynamic motion of the i-motif 
DNA strands and aggregational behaviour of AuNPs 
to elicit programmed delivery of therapeutic siRNA. 
siRNA N/A Luciferase NIH3T3 N/A 
The i-motif DNA formed an interstrand 
tetraplex, which could induce cluster 
formation of AuNPs resulting in 
endosomal escape and higher gene 
silencing efficiency. Furthermore, the 
cluster formation of AuNPs accelerated 
photothermal ablation of cells when 
irradiated with laser.  
 
[102] 
Spherical nucleic acid nanoparticle conjugates (SNA-
NCs) were synthesized by the attachment of thiolated 
siRNA to citrate-stabilised AuNPs creating a densely 
packed NP with siRNA surrounding an inorganic 
gold core. 





AuNPs successfully reduced 
Bcl2L12 expression both in vitro and in 
vivo following systemic IV injection. In 
addition SNA-NCs increased tumoural 
apoptosis, reduced tumour burden and 
decreased tumour progression in 




SNA-NCs were synthesized via thiol-gold chemistry 
between hybridized siRNA duplexes and citrate-
stabilized gold colloids. Salt was added to shield 











hairless mouse  
SNA-NCs delivered in vitro achieved 
more persistent EGFR knockdown than 
the commercial vector DharmaFECT1 
and achieved similar levels of 
knockdown with 100-fold less siRNA. In 
both mouse strains, SNA-NCs penetrated 
through the stratum corneum as little as 3 
hours after application. Topical delivery 
of EGFR siRNA for 3 weeks to hairless 
mouse skin significantly reduced EGFR 
expression, without toxicity. 
 
[104] 
Citrate-stabilised AuNPs were conjugated with a 25% 
PEG surface layer. The Au surface of PEG-AuNPs 
was then functionalised with RGD peptide for 

















The targeted AuNP formulation 
mediated successful integrin binding, 
cellular uptake and C-myc 
downregulation in vitro. Intratracheal 
instillation significantly reduced c-myc 
 
[105] 







expression and inhibited tumour growth 
with resulting significantly increased 
survival. 
Core/shell-structured hollow gold nanospheres 
(HAuNS) sensitive to near-IR (NIR) light-induced 
siRNA release were conjugated by thiolation with an 
siRNA duplex (HAuNS-siRNA). A folate targeting 
ligand was then added using folate-targeted PEG-



















In vitro, NIR radiation resulted in the 
loss of HAuNS structural integrity and 
subsequent siRNA dissociation leading 
to significantly reduced p65 expression. 
Targeted NPs exhibited significantly 
higher tumour uptake in xenografted 
mice compared to non-targeted 
counterparts following intravenous 
injection. Irradiation with NIR light 
achieved downregulation of NF-κB p65. 
In contract, no downregulation was 
attained in non-irradiated tumours grown 
in the same mice. 
 
[106] 
Electrostatic interaction  
Cationic cysteamine-AuNPs were used to 
electrostatically bind miRNA, followed by the 
addition of thiolated-PEG chains to cover the 
cysteamine-free surface. 










N/A PEG-AuNPs-miRNA was non-cytotoxic 
and demonstrated effective cellular 
uptake and miRNA release, which 
specifically regulated target gene 




PEI-capped AuNPs (manufactured using PEI as the 
reductant and stabiliser) complexed with siRNA 



















PEI-AuNP-siRNA successfully reduced 
GFP expression and NPs containing 
antiPLK1 siRNA showed significant 
PLK1 protein reduction. In addition, the 




AuNPs were synthesised by attaching PEG-thiol as a 
stabilising ligand to the surfaces of AuNPs. siRNA 
was condensed with protamine to achieve 
‘protamine.siRNA’ which was further complexed 















This formulation demonstrated effective 





PEI-stabilised AuNPs were used to complex siRNA 














siRNA-PEG-AuNPs were introduced 
into cells by electroporation. Gene 
silencing using siRNA was significantly 




AuNPs were anchored by catechol-conjugated PEI 
(PEI-C) resulting in robust cationic PEI-C-AuNPs 
which were further modified with a small amount of 
thiolated PEG. PEI-C-AuNPs formed stable 













siRNA-PEI-C-AuNP complexes showed 
effective cellular uptake, endosomal 
release and GFP suppression, without 
showing significant cytotoxicity. 
 
[110] 
Cationic lipid-coated AuNPs (L-AuNPs) were formed 
by co-dissolving hydrophobic dodecanethiol-capped 
AuNPs with three lipid components (DC-chol, DOPE 
and cholesterol) in organic solvent and using an 
emulsification/solvent evaporation process to form 
NPs with an outer cationic lipid shell and an inner 
gold NP cluster core.  These cationic L-AuNPs could 


































L-AuNPs were able to bind siRNA to 
form polyelectrolyte complexes which 
efficiently delivered siRNA into cancer 
cells and significantly suppressed target 
gene expression. In addition these L-
AuNPs did not show severe cytotoxicity 




Amine-functionalized gold nanoparticles (AF-
AuNPs) were synthesized through chemical reduction 
of gold precursor anions in the presence of 
cysteamine hydrochloride on addition of sodium 
borohydride. siRNA-PEG was synthesized with a 
disulphide link capable of being cleaved in the 
reductive environment of the cytoplasm. This was 











The PEG chain improved the stability of 
the complexes by protecting them from 
aggregation. PEG-siRNA/AF-AuNPs 
had higher cell internalisation than 
siRNA/AF-AuNPs and significantly 
suppressed GFP expression. It achieved 
gene knockdown levels comparable to 
PEI but without the severe cytotoxicity 
associated with this vector. 
 
[112] 
Dendronised AuNPs were synthesized to create 
ligands with biodegradable glutamic acids scaffolds 
and cationic TETA moieties that were able to 













Complexation of siRNA with 
dendronised AuNPs produced efficient 
gene silencing (∼50%) comparable to 





PEI-capped AuNPs were conjugated with EpCAM 
monoclonal antibody for targeting the Epithelial Cell 
Adhesion Molecule (EpCAM) on the surface of cells. 
The resulting antibody-targeted PEGI-AuNPs were 


















EpCAM antibody conjugated PEI-
AuNPs loaded with siRNA showed 
greater uptake and enhanced gene 
silencing efficacy when compared to 
siRNA-PEI-AuNPs synthesized without 




Layer-by-layer self-assembly  
 
Denatured BSA (dBSA) was first coated onto the 
surface of AuNPs creating negatively charged dBSA-
AuNPs. These were electrostatically coated with a 
cationic polymer (either PAH, PEI or PDDA) to form 
a positive layer which could be used to bind siRNA. 
Finally, the siRNA layer was electrostatically coated 
with the same cationic polymer again to form a 


















Confocal microscopy studies indicated 
PEI-AuNPs and PAH-AuNPs can induce 
better siRNA release than PDDA-
AuNPs. In addition, PEI and PAH-
AuNPs demonstrated gene knockdown 
levels significantly better than both 




The surface of citrate-AuNPs was modified by 
mercaptoundecanoic acid (MUA) resulting in 
negatively charged MUA-AuNPs. The resulting 
MUA-AuNPs were electrostatically interacted with 
PEI (PEI/MUA-AuNPs) which formed a cationic 
layer which was coated by PAH-Cit (PAH/PEI/MUA-
AuNPs). PAH/PEI/MUA-AuNPs were 
electrostatically coated with PEI 
(PEI/PAH/PEI/MUA-AuNPs) which resulted in 
positively charged particles that could 














PAH-Cit, a pH-dependent charge-
reversal polymer, remains negative in 
physiological pH but changes to cationic 
at pH 5-6. Confocal microscopy studies 
implied that PEI-PAH-PEI-MUA-
AuNPs released more siRNA into the 
cytoplasm compared to other controls. 
This formulation demonstrated improved 




Negatively charged AuNPs were coated with PLL to 
generate a cationic surface that was used to complex 
siRNA forming siRNA/PLL/AuNPs.  The coating 
procedure was repeated numerous times and resulted 
in a final formulation with 4 layers of PLL and 3 














siRNA was released gradually from 
PLL-AuNPs and showed extended gene 
silencing effect, which is most likely due 
to slow degradation of PLL. Importantly, 
the inhibition effect in cells was found to 
correlate with the number of siRNA 
layers. The NP was more effective than 
Lipofectamine but with less toxicity. 
 
[117] 
AuNPs were reduced and stabilised by chitosan (CS), 
forming a positively charged CS-AuNP core which 
was coated by PAH-Cit (PAH/CS-AuNPs). This 
formed NPs with an anionic layer which were 
electrostatically coated by PEI, producing cationic 
PEI/PAH/CS-AuNPs. This was subsequently used to 















N/A Specific silencing of MDR1, a gene 
encoding the drug exporter P-gp, was 
achieved using the resulting formulation, 
which promoted the uptake of 
doxorubicin. This is an anticancer agent 
known to be effluxed from cells by P-gp 
resulting in treatment failure. 
 
[118] 
Citrate-AuNPs were modified by 
mercaptoundecanoic acid (MUA) resulting in 
negatively charged MUA-AuNPs. The resulting 
MUA-AuNPs were electrostatically interacted with 
PEI (PEI/MUA-AuNPs) forming a cationic layer 
which was used to complex siRNA 












N/A These layer-by-layer formulations 
provided an excellent tool to study how 
the size and the surface properties 
influence the portal of entry into cells 
and direct distinct particles to the correct 
site of activity. The NPs were able to 
mediate significant gene knockdown 
 
[119] 
coated by PEI forming PEI/siRNA/PEI/MUA-
AuNPs. 
without affecting cell viability. 
A positively charged CTAB-modified gold nanorod 
was coated with two layers of polyelectrolytes, 













In vitro BBB 
models 
 
N/A This multilayer process generated 
positively AuNPs that ‘masked’ the 
CTAB layer which is notorious for its 
cytotoxicity.  The resulting siRNA 
complexes achieved target gene 
knockdown in DAN cells without 
significant cytotoxicity. More 
importantly, these complexes 
demonstrated successful transmigration 
across an in vitro model of the blood-
brain barrier (BBB).  
 
[120] 
A positively charged CTAB-modified gold nanorod 
was coated with two layers of polyelectrolytes, 




















Nanoplexes formed by electrostatic 
binding between siRNA and positively 
charged GNRs silenced the expression of 
the GAPDH housekeeping gene (70% 
GAPDH silencing, >10 days post-
injection), within the CA1 hippocampal 




Cationic cysteamine-modified AuNPs were coated by 
siRNA (siRNA/CM-AuNP), followed by addition of 
PEI forming PEI/siRNA/CM-AuNPs. Positively 
charged PEI/siRNA/CM-AuNPs were further coated 
























The resulting formulation selectively 
delivered anti-VEGF siRNA into HA 
receptor-positive cells and resulted in 
reduced VEGF expression. In addition, 
the NPs mediated significant Luciferase 
gene knockdown and systemic 
administration containing anti-ApoB 
siRNA effectively decreased expression 
of the targeted gene in the liver of mice. 
 
[123] 
 
